Journal
VACCINE
Volume 38, Issue 49, Pages 7702-7707Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2020.09.042
Keywords
Brighton Collaboration; CEPI; COVID-19; Vaccine; Benefit-risk; Safety; Live; Attenuated; Viral; Template
Categories
Funding
- Coalition for Epidemic Preparedness Innovations (CEPI)
Ask authors/readers for more resources
Several live-attenuated viral vaccine candidates are among the COVID-19 vaccines in development. The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) has prepared a standardized template to describe the key considerations for the benefit-risk assessment of live-attenuated viral vaccines. This will help key stakeholders assess potential safety issues and understand the benefit-risk of such vaccines. The standardized and structured assessment provided by the template would also help to contribute to improved communication and support public acceptance of licensed live-attenuated viral vaccines. (C) 2020 The Author(s). Published by Elsevier Ltd.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available